Cell Therapy Group Announces Expansion of Consultants Roster in Regenerative Medicine

Share Article

Regenerative medicine & medical device experts join cell therapy consulting firm

News Image
Sarah's breadth of expertise ranges from tissue engineering to stem cells and cell therapy

Cell Therapy Group is pleased to formally announce the addition of three new team members including Sarah A. Haecker, PhD as Director, Regenerative Medicine Business, Daniel A. Segal, as Director, Stem Cell & Medical Device Business, and John E. Hambor, PhD as Director, Stem Cell-based Drug Discovery.

“I am proud to be working with Sarah, Dan, and John as members of the Cell Therapy Group and am excited by the expertise this brings to the company and its clients,” says CTG Founder and Managing Director, Lee Buckler.

“Sarah’s breadth of expertise ranges from tissue engineering to stem cells and cell therapy”, continues Mr. Buckler. “She brings to our clients a focus on the essential elements of commercially viable product development and the corporate strategies required for their success. Sarah combines a solid technical background and understanding of the science of regenerative medicine with an outstanding and insightful business acumen and expertise honed over her executive career in the industry. She is the consummate business development professional who excels in putting parties together and driving deals to fruition.”

“Similarly,” says Buckler, “Dan Segal has a stellar track record of achieving top and bottom-line success for companies throughout the medical device and cell therapy industries. He has proven expertise in building and managing domestic and international sales through direct and distributor channels for companies ranging from start-ups to Fortune 500 companies. Dan brings to CTG’s clients a depth of industry expertise that comes from years of executive experience working for companies in the cell therapy and stem cell space.”

Finally, John Hambor will extend CTG’s offering into the exciting arena of cell-based and tissue engineering technologies as tools for drug discovery, screening, and toxicology testing. “John brings not only scientific breadth and depth to the firm but he has the ability to leverage his successful career in the pharmaceutical industry in the strategic commercialization of cell-based technologies,” says Sarah Haecker, who has previously collaborated with Hambor.

“John brings to CTG and its clients his broad perspective of utilizing stem cell technologies across the entire drug discovery process. With a deep understanding of regenerative medicine, cell therapy, tissue engineering, and classic pharmaceutical drug development, he provides his clients with a unique combination of technical and business knowledge for business development, strategic planning, product development, market analysis, licensing, patent protection of intellectual property, and partnering & coalition building.”

Sarah A. Haecker

Prior to joining CTG, Sarah was an independent business strategist in the Regenerative Medicine Industry. With more than 16 years of senior-level management experience she uniquely combines technical and business knowledge with emphasis in strategy, business development, licensing, opportunity assessment, market analysis and partnering early to late stage technologies in the private and public sectors.

Dr. Haecker’s client list encompasses big pharma to emerging regenmed and stem cell based companies, investment banking and venture to academia. She has both published and spoken to a world-wide audience in the area of progressive, innovative stem cell science and specifically on business modeling in the ReGEN Industry. With postdoctoral training in the School of Medicine and Gene Therapy Program at the University of Pennsylvania, Sarah has a broad technical knowledge base in regenerative medicine, tissue engineering, stem cell biology and application, gene and cell therapy, translational research, and clinic applications.

Daniel A. Segal

Dan brings over 25 years of experience in the medical device industry with more than 12 of those years focused in the area of emerging stem cell therapies where he held various senior and executive management positions in sales, marketing, business development, and operations, with start-up, small, medium and Fortune 500 companies.

During the course of his career Dan has been responsible for strategic planning, business planning, launching new products into worldwide markets, building and managing international distribution channels, and identifying and establishing relationships with strategic partners.

John E. Hambor

As a former Pfizer scientist and founding member of their stem cell research unit overseeing global efforts in stem cell technologies as part of the Genetically Modified Models Center of Emphasis, Dr. John Hambor has over 20 years of research, management and training experience in both the pharmaceutical and biotechnology industries.

As a skilled hands-on scientist, executive and new business architect, Dr. Hambor has core competencies in multiple areas including:

  •     Basic Research (stem cell biology, drug discovery, transgenic animals, molecular biology and genetics)
  •     Process Development (optimization of stem cell expansion & differentiation into multiple somatic cell types, RNAi & small molecule screening, recombinant protein production)
  •     Clinical Manufacturing (SOPs, batch records, automated large-scale cell culture)
  •     Project Management (project design & implementation, process reengineering, strategic planning)
  •     Supervision (team building, talent development, team & organizational alignment)
  •     External Collaboration (corporate, academic)

Dr. Hambor received a Ph. D. in Pathology from Case Western Reserve University and subsequently moved on to Yale where he did post-doctoral studies in Immunology.

the Cell Therapy Group

Cell Therapy Group, a division of CTG Consulting, Co. is a consultancy for companies in the cell therapy and regenerative medicine sectors as well as companies using or looking to use stem cells in drug discovery.

###

Share article on social media or email:

View article via:

Pdf Print